Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

June 30, 2024

Conditions
Allergic Rhinitis
Interventions
DRUG

Bencycloquidium Bromide Nasal Spray

"The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.~This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis."

DRUG

Mometasone Furoate Aqueous Nasal Spray

"Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.~This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment."

Trial Locations (6)

Unknown

Beijing friendship hospital, CMU, Beijing

Beijing Shijitan Hospital,CMU, Beijing

Beijing Tongren Hospital,CMU, Beijing

The third affliation hospital of Sun YAT-SEN university, Guangzhou

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

Jiangsu Province hospital, Nanjing

All Listed Sponsors
lead

Yingu Pharmaceutical Co., Ltd

INDUSTRY